109 completed, 12 terminated, 11 unknown, 9 withdrawn. 70 Phase 2, 30 Phase 4, 23 Phase 1, 19 Phase 3, 16 Not applicable.
Follow Cyclosporins: new trials by email Literature Review of Cyclosporins trials Research Report on Cyclosporins
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Aplastic Anemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 1 | 2025-09-25 | 2026-05-22 |
| Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide - Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 54 | 2024-07-23 | 2026-07-22 |
| Cyclosporine and Intense Pulsed Light for Dry Eye in Contact Lens Users CycloSPORINE Ophthalmic, Intense Pulsed Light, Sham Intense Pulse Light - Dry Eye, Contact Lens Complication | Phase 3 | Unknown | Université de Sherbrooke | 44 | 2024-04-25 | 2024-05-01 |
| Tear Film Markers in Dry Eye Syndrome Cyclosporine, Artificial tear - Dry Eye | Phase 4 | Withdrawn | Vishal Jhanji | 2023-12-08 | 2023-12-18 | |
| The COAT Trial: Cequa's Onset of Action Trial Cyclosporine ophthalmic solution - Dry Eye | Phase 4 | Completed | Research Insight LLC | 52 | 2023-10-12 | 2024-07-01 |
| Improving Drop Instillation Comfort of a Cyclosporine A Solution 0.09% cyclosporine A ophthalmic solution - Dry Eye Disease | Not applicable | Completed | University of Waterloo | 40 | 2023-05-19 | 2024-08-09 |
| HU007 in Patients with Dry Eye Syndrome HU007, Restasis, Moisview Eye drop - Dry Eye Disease | Phase 3 | Completed | Huons Co., Ltd. | 328 | 2023-03-23 | 2024-09-26 |
| Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies. Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG) - Hematologic Malignancy, Myeloid Malignancy | Phase 2 | Terminated | St. Jude Children's Research Hospital | 3 | 2023-03-14 | 2025-10-02 |
| A Feasibility Study to Evaluate the Tolerability of Oph1 Compared to Restasis in Healthy Volunteers Oph1, Restasis - Dry Eye Syndromes | Early Phase 1 | Completed | OphRx Ltd. | 20 | 2023-01-23 | 2024-04-05 |
| Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis SCAI-001 0.01% eyedrop, SCAI-001 0.02% eyedrop, Restasis 0.05% eyedrop - Dry Eye Syndromes | Phase 2 | Completed | SCAI Therapeutics | 116 | 2023-01-05 | 2024-02-05 |
| Clinical Trial To Determine The Effectiveness And Safety Of Topical Insulin In Dry Eye Insulin, Cyclosporins, Artificial tears - Dry Eye, Insulin | Phase 4 | Completed | Barbara Burgos Blasco | 116 | 2022-10-19 | 2026-03-05 |
| Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device Restasis - Ocular Surface Disease | Phase 1 / Phase 2 | Completed | Boston Sight | 10 | 2021-07-15 | 2025-01-13 |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Anti-Thymocyte Globulin, Busulfan, Cyclophosphamide - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2021-06-01 | 2021-06-30 | |
| Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA) TearCare System, Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion - Dry Eye, Meibomian Gland Dysfunction | Not applicable | Completed | Sight Sciences, Inc. | 345 | 2021-04-28 | 2025-11-24 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2021-01-25 | 2026-05-29 |
| A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3% - Dry Eye Disease | Phase 2 | Completed | Surface Ophthalmics, Inc. | 349 | 2021-01-11 | 2025-05-11 |
| Topical Cyclosporin A 0.05% Eye Drops for Management of Symptomatic Acquired Punctal Stenosis. A Prospective, Controlled Clinical Study. 0.05% cyclosporin (Restasis®, Allergan Inc), mini-monoka stent - Management of Punctal Stenosis | Not applicable | Completed | Farwaniya Hospital | 42 | 2021-01-01 | 2023-03-16 |
| ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops - Dry Eye Disease | Phase 3 | Completed | Novaliq GmbH | 834 | 2020-12-05 | 2023-03-10 |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia Cladribine, Cyclophosphamide, Cyclosporine - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 120 | 2020-12-03 | 2026-09-17 |
| Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders Clofarabine, Fludarabine, Busulfan - AML, ALL | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 31 | 2020-11-20 | 2026-03-13 |
Showing 20 of 151. Sign in to see all of them.
Dry Eye Syndromes (42) · Leukemia, Myeloid, Acute (26) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (22) · Leukemia, Lymphocytic, Chronic, B-Cell (20) · Hodgkin Disease (19) · Myelodysplastic Syndromes (19) · Lymphoma, Non-Hodgkin (16) · Leukemia, Myelomonocytic, Chronic (14) · Lymphoma, Mantle-Cell (14) · Myeloproliferative Disorders (14) · Multiple Myeloma (13) · Lymphoma, Large B-Cell, Diffuse (12) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (11) · Leukemia, Myeloid, Chronic-Phase (11) · Anemia, Aplastic (10)
Fred Hutchinson Cancer Center (34) · Allergan (7) · Innovative Medical (5) · Huons Co., Ltd. (4) · Eastern Cooperative Oncology Group (3) · M.D. Anderson Cancer Center (3) · Case Comprehensive Cancer Center (2) · Children's Oncology Group (2) · Farwaniya Hospital (2) · Hospices Civils de Lyon (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Northwestern University (2) · Novaliq GmbH (2) · Panacea Biotec Ltd (2) · Research Insight LLC (2)
United States (106) · Canada (9) · Italy (7) · South Korea (7) · China (6) · Germany (6) · Australia (3) · Denmark (3) · France (3) · India (3) · Kuwait (3) · Brazil (2) · Spain (2) · Austria (1) · Egypt (1)
Brenda Sandmaier (10) · Danielle M Townsley, M.D. (2) · David Maloney (2) · Dr Nirav Gandhi (2) · Filippo Milano (2) · John Hovanesian, MD (2) · Lauri Burroughs (2) · Marco Mielcarek (2) · Masumi Ueda Oshima (2) · Sandeep Soni, MD (2) · Sonja Kroesser, PhD (2) · Aida Lugo-Somolinos, MD (1) · Ajay Gopal (1)
PMID 32499241, PMID 34724566, PMID 10434857, PMID 10768324, PMID 10815152, PMID 11009316, PMID 11567963, PMID 11685055, PMID 11879137, PMID 12006334, PMID 12657587, PMID 14508260, PMID 15061852, PMID 15090417, PMID 15489495, PMID 15733983, PMID 15753371, PMID 16004673, PMID 16102833, PMID 16785864, PMID 17102664, PMID 17262232, PMID 17508121, PMID 18035553, PMID 18424759, PMID 18557726, PMID 18703875, PMID 18813071, PMID 18848318, PMID 19006483, PMID 19066739, PMID 19128374, PMID 19218606, PMID 19730088, PMID 20092592, PMID 20155706, PMID 20236866, PMID 21508120, PMID 21606164, PMID 21663651, PMID 21792057, PMID 22157574, PMID 22232476, PMID 22606467, PMID 22670856, PMID 22776430, PMID 22830463, PMID 22928476, PMID 22955119, PMID 23206408
P30CA015704 (27), P01CA018029 (7), P01CA078902 (6), P01CA044991 (3), U10CA021115 (3), 2009 (1), K12HD043494 (1), K23CA190849 (1), P01CA049605 (1), P01HL036444 (1), P30CA016672 (1), P30CA022453 (1), P30CA036727 (1), P30CA068485 (1), R01AI047040 (1)